OpGen

OpGen EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of OpGen (OPGN) as of Oct 30, 2026 is 15.20. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 913.40 — a change of -98.34% (lower).

EV/EBIT

15.20

YoY

-98.34%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of OpGen is 2025 15.20 . EV/EBIT (Enterprise Value to EBIT) of OpGen was 2024 913.40 . It decreases by -98.34% lower compared to the previous year.

The OpGen EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-27.71 USD
Jan 1, 2019
-29.76 USD
Jan 1, 2020
-16.99 USD
Jan 1, 2021
-15.69 USD
Jan 1, 2022
-16.44 USD
Jan 1, 2023
-23.28 USD
Jan 1, 2024
913.40 USD
Jan 1, 2025
15.20 USD
The OpGen EV/EBIT history
YEAREV/EBITYoY
15.20-98.34%
913.40-4,023.42%
-23.28+41.63%
-16.44+4.74%
-15.69-7.64%
-16.99-42.91%
-29.76+7.41%
-27.71+15.62%
-23.97+24.74%
-19.21-23.55%
-25.13-61.71%
-65.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides OpGen's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates OpGen's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots OpGen's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if OpGen grows earnings faster than its peers.

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

EV/EBIT (Enterprise Value to EBIT) of OpGen is 15.20 in 2025.

EV/EBIT (Enterprise Value to EBIT) of OpGen changed from 913.40 to 15.20, representing a -98.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) OpGen since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OpGen

All Key Metrics — OpGen